Pulse Biosciences (PLSE) Expected to Announce Earnings on Wednesday

Pulse Biosciences (NASDAQ:PLSE) is expected to be releasing its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Pulse Biosciences to post earnings of ($0.31) per share and revenue of $0.50 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02).

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE opened at $18.08 on Wednesday. The company has a 50 day moving average price of $16.91 and a 200 day moving average price of $16.42. Pulse Biosciences has a 1-year low of $13.77 and a 1-year high of $25.00. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -17.22 and a beta of 1.79.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on PLSE shares. Oppenheimer started coverage on shares of Pulse Biosciences in a research note on Monday, July 7th. They issued an “outperform” rating and a $22.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $22.00.

Insiders Place Their Bets

In other Pulse Biosciences news, CTO Darrin Uecker sold 20,000 shares of the stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $16.21, for a total value of $324,200.00. Following the completion of the sale, the chief technology officer owned 122,872 shares in the company, valued at $1,991,755.12. This represents a 14.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin Patrick Danahy sold 4,600 shares of the stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $18.53, for a total transaction of $85,238.00. Following the completion of the sale, the insider owned 43,298 shares of the company’s stock, valued at approximately $802,311.94. The trade was a 9.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 95,000 shares of company stock worth $1,550,380 in the last quarter. 74.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLSE. Jane Street Group LLC purchased a new stake in Pulse Biosciences in the 1st quarter worth approximately $323,000. Creative Planning raised its holdings in shares of Pulse Biosciences by 26.3% during the 2nd quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after purchasing an additional 3,951 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Pulse Biosciences by 57.7% during the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock valued at $338,000 after purchasing an additional 8,197 shares in the last quarter. Norges Bank bought a new position in shares of Pulse Biosciences during the 2nd quarter valued at $302,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Pulse Biosciences during the 2nd quarter valued at $158,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.